Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Low-dose aspirin reduces cardiovascular events

16.11.2006
Taking low-dose aspirin daily reduces the risk of heart attack and stroke, as well as the risk of dying, among patients who previously have had a heart attack or stroke but whose cardiovascular disease has stabilized, according to a new analysis by Duke University Medical Center cardiologists.

The study also found that taking low-dose aspirin daily increases a patient's risk of bleeding, but the researchers said the protective benefits of aspirin outweigh this side effect. A daily dose of aspirin is considered low if it is between 81 milligrams and 325 milligrams.

"Among patients with stable cardiovascular disease, we found that low-dose aspirin reduced incidence of heart attack, stroke and death," said cardiology fellow Jeffrey Berger, M.D., who presented the results of the study on Wednesday, Nov. 15, at the annual scientific sessions of the American Heart Association, in Chicago.

"We also saw an increased risk of bleeding among patients taking aspirin, but as in the decision-making process involving any therapy, there is always the weighing of benefits and risks," Berger added. "Since a great majority of patients can tolerate aspirin, the benefits appear to outweigh the risks. Aspirin is a drug that has been used for many years. It is well-understood, effective, inexpensive and widely available. In aspirin we have a proven life-saver."

The study was supported by Duke's Division of Cardiology.

Aspirin exerts its protective effect by preventing the clumping together of platelets circulating in the blood, according to the researchers. It is this anticlotting action that also causes unwanted bleeding.

In the Duke study, Berger and colleagues combined the data from six clinical trials that enrolled patients with stable cardiovascular disease or stable angina, or chest pain, and gave them low-dose aspirin. In total, the trials included 9,853 patients.

The researchers found that patients who took low-dose aspirin had a 26 percent reduction in the risk of a nonfatal heart attack, a 25 percent reduction in the risk of stroke and a 13 percent reduction in risk of death, compared with similar heart patients who did not take aspirin. Taken together, Berger said, patients on low-dose aspirin had a 21 percent reduction in risk of experiencing a major cardiovascular event, a measurement that is the combination of the rates of nonfatal heart attack and stroke and of cardiovascular death.

In terms of aspirin's effect in promoting bleeding, the study found that one patient out of 111 who received low-dose aspirin experienced a bleeding episode, Berger said.

Putting the results another way, Berger said, the results suggest that treating 83 patients will prevent one nonfatal heart attack, treating 40 patients will prevent one stroke, treating 30 patients will prevent one major cardiovascular event and treating 71 patients will prevent one death.

"When compared to other medications that have been proven effective in preventing cardiovascular events, aspirin comes off looking very good," Berger said.

For example, 91 patients would need to be treated with ACE inhibitors to prevent one death, compared with 71 patients for aspirin, he said. ACE inhibitors dilate blood vessels, making it easier for the heart to pump blood. Ninety-one patients would need to be treated with the inhibitors to prevent one heart attack, compared with 83 for aspirin, and 167 would need to be treated with the inhibitors to prevent one stroke, compared with 40 patients with aspirin.

"These comparisons show that a cheap and inexpensive medicine like aspirin is just as good, if not better, than other expensive medicines," Berger said.

Still, there is room for improvement in aspirin therapy, he said. In particular, he said, more study is needed to identify what dosage in the low-dose range -- from 81 milligrams to 325 milligrams a day -- will provide the best benefit-to-risk profile.

Richard Merritt | EurekAlert!
Further information:
http://www.mc.duke.edu

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>